Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results?

Pfizer posted strong Q2 2025 results, surpassing EPS and revenue estimates, driven by key product sales and a strengthened oncology pipeline following the Seagen acquisition, which is expected to underpin a 6% revenue CAGR through 2030. However, significant headwinds persist, including declining COVID product sales, an impending 2026-2030 loss of exclusivity cliff, and an $875 million Q2 impact from Medicare Part D redesign under the IRA, compounded by the discontinuation of its GLP-1 program and potential future tariff threats. Pfizer aims to mitigate these challenges through $7.7 billion in cost savings by 2027 and R&D productivity, positioning itself as a value and income opportunity given its attractive valuation and 7% dividend yield, despite the mixed outlook.

Analysis

Pfizer demonstrated strong operational performance in its second-quarter 2025 results, beating consensus estimates with a 10% year-over-year revenue increase to $14.7 billion and a 30% rise in adjusted EPS to 78 cents. The performance was driven by the growth of key products like Vyndaqel and Padcev, the stabilization of its COVID franchise, and a 15% operational revenue increase from its recently launched and acquired products in the first half of 2025. The company's strategic pivot towards oncology, fortified by the Seagen acquisition, is showing early results with a 9% revenue growth in the segment for H1 2025 and a pipeline ambition of over eight blockbuster oncology drugs by 2030. Despite this positive momentum, which led management to raise its full-year adjusted EPS guidance, significant headwinds persist. The Inflation Reduction Act's (IRA) Medicare Part D redesign already impacted U.S. revenues by $875 million in Q2, and the company faces a major loss of exclusivity cliff for several key products between 2026 and 2030. Furthermore, Pfizer has ceded the lucrative GLP-1 weight-loss market to competitors after discontinuing its danuglipron program and faces potential political risks from proposed tariffs and drug pricing policies. The stock appears financially attractive, trading at a forward P/E of 7.93 versus the industry's 13.71 and offering a substantial dividend yield of approximately 7%, presenting a classic value case against a backdrop of tangible long-term risks.

Key Decisions for Investors

• Value and income-focused investors may find the stock's low forward P/E of 7.93 and high dividend yield of around 7% compelling, but this must be balanced against significant forward-looking risks.
• Investors should closely monitor the execution of the Seagen integration and the progress of the oncology pipeline, as these are critical factors for offsetting the anticipated revenue erosion from the 2026-2030 patent cliff.
• The discontinuation of the GLP-1 program signals a competitive gap in a major growth market, suggesting investors seeking exposure to the obesity drug boom should look to competitors like Novo Nordisk and Eli Lilly.
• Holders should be aware of material external risks, including the ongoing financial impact of the IRA's Medicare changes and potential volatility from future U.S. tariff and drug pricing legislation.